(Press-News.org) A visionary $100 million matching grant from the Weill Family Foundation is bringing together two leading cancer centers to launch the Weill Cancer Hub West -– an innovative collaboration among some of the nation’s most talented scientists that will transform cancer research and care in the next decade.
The initiative will harness the expertise and resources of two world-class institutions -– the UCSF Helen Diller Family Comprehensive Cancer Center and the Stanford Cancer Institute -– to lead cross-specialty collaborations that accelerate new discoveries and speed the development of innovative new treatments for patients.
The new hub is supported by funding from Joan and Sanford I. Weill via the Weill Family Foundation. The two partner institutions have committed to raising $50 million apiece in matching gifts, bringing the total support to $200 million over 10 years. The initiative will launch with more than $25 million* in philanthropy already in place toward the matching goal.
Despite decades of advances in research and therapies, cancer is still on the rise, with nearly 20 million new cases and approximately 10 million deaths worldwide each year. Yet many scientists believe we are at a turning point, as revolutions in biology and immunology converge with advances in artificial intelligence technology and data science. The result is an unprecedented chance to drive real changes for patients.
“Good things happen when people collaborate,” Sandy Weill said. “UCSF and Stanford have long been engines of innovation and biotechnology, and today they are poised to shape the future. With the combined power of the brightest scientific minds and AI capabilities, the Weill Cancer Hub West will develop new ways to detect cancers at their very earliest stages, create advanced new treatments, and help patients live longer and better lives. Joan and I could not be more excited about the possibilities of this initiative.”
“The fight against cancer is one of the defining health challenges of our time,” said Stanford President Jonathan Levin, PhD. “Stanford and UCSF are well positioned to advance the collaborative, next-generation research that will make a meaningful difference in the lives of countless people in America and around the world. We are grateful to Joan and Sandy Weill for their vision and commitment to this important cause.”
The groundbreaking value of collaborative science
The Weill family and their foundation are long-time champions of exceptional science and medicine, with a particular focus on the power of philanthropy to forge scientific collaborations at multiple top-tier institutions.
The Weill Cancer Hub West is the culmination of several years of planning between the Weills and the two founding institutions and is expected to transform the field of cancer research. By unifying the research within a collaborative hub, the initiative will forge partnerships that break down silos and foster collaboration among innovative scientific leaders.
It also will set up a sustainable model of collaborative research between the two institutions, using the hub's scientific advances to inspire additional philanthropic support and competitive grant funding, generate new patents and intellectual property to support the universities’ research enterprises, and spin out companies to help bring those advances to market.
“Joan and Sandy Weill have a unique ability to see beyond what currently exists in a single institution or scientific program and support collaborations that will fundamentally reshape the way we treat the most devastating diseases of our time,” said UCSF Chancellor Sam Hawgood, MBBS, chancellor and the Arthur andToni Rembe Rock Distinguished Professor at UCSF. “Their generosity and vision for collaborative science will accelerate revolutions in health that will help patients everywhere.”
This is the second cancer hub of its kind, following the March announcement of the Weill Cancer Hub East with four institutions on the East Coast: Weill Cornell Medicine, Princeton University, The Rockefeller University, and the Ludwig Institute for Cancer Research.
Both hubs are modeled on the success of the Weill Neurohub. Launched in 2019, it is now a vibrant network of researchers and clinicians from UCSF, UC Berkeley, the University of Washington, and the Allen Institute that is focused on accelerating new treatments for neurological and psychiatric diseases.
In total, the Weill family and their foundation have contributed more than $400 million to groundbreaking scientific research and patient care in the San Francisco Bay Area, and more than $1 billion to nonprofits in the United States and around the globe.
"This collaboration exemplifies the power of philanthropy in advancing science and health care," said Lloyd Minor, MD, the Carl and Elizabeth Naumann Dean of the School of Medicine and vice president for medical affairs at Stanford University. “Establishing the Weill Cancer Hub West will accelerate our ability to develop targeted therapies and transform our fight against cancer. We are immensely grateful to Joan and Sandy Weill for enabling us to continue to bring the most promising therapies to patients.”
Four initial projects at the edge of medical research
The Weill Cancer Hub West will drive innovations in three key areas: human cells and tissues to better understand how cancer develops and affects each individual patient; data science to drive early detection, diagnoses, and effective treatments; and new therapies to overcome drug resistance and inadequate responses.
It will launch with four cross-functional projects that will bring together scientists, including a Nobel laureate, at the pinnacle of their fields. Each project has a 10-year target impact:
Project VITAL, to create a new generation of cellular therapies, using CRISPR technology to engineer immune cells inside the body;
Project PROMISE, leveraging artificial intelligence and cellular engineering to safely and precisely destroy the most treatment-resistant solid tumors;
Project FEAST, to identify and optimize diet and drug interventions to reduce cancer development, progression, and metastasis; and
Project IMPACT to build artificial intelligence systems that integrate clinical and biological data for precise, personalized cancer treatments.
The first two projects will focus on radically increasing the availability and success of cellular therapies such as CAR-T, which is already improving the lives of many patients with blood cancers. But those cellular therapies are expensive and challenging to manufacture and deliver to patients.
Project VITAL is linking UCSF and Stanford researchers with Nobel-prize winning techniques to develop the next generation of immune cells that can be generated inside the patient’s body, creating a flexible and personalized therapy.
Project PROMISE will address the 90% of cancers that are solid tumors, which are notorious for evading immune therapies. Researchers at both UCSF and Stanford are creating cellular therapies that can overcome those obstacles. Over the next decade, they aim to use AI to analyze millions of immune cells from patients who have received cellular therapies to identify changes that make these therapies more effective – and then use that knowledge to produce immune cells that can destroy solid tumors anywhere in the body.
Precision therapies from cell engineering to nutrition
“UCSF and Stanford are leaders in developing cellular therapies that are already transforming the way we treat blood cancers,” said Alan Ashworth, PhD, FRS, president of the UCSF Helen Diller Family Comprehensive Cancer Center and the E. Dixon Heise Distinguished Professor in Oncology at UCSF. “This collaboration will be a major step in helping our teams advance those therapeutics to safely treat tumors.”
The teams will also be studying how the new diabetes drugs impact cancer and which foods slow cancer’s progression or reduce the chance of getting it in the first place. Early data suggest that people who use the newly available GLP-1 medications like Ozempic and Mounjaro show reduced rates of cancer. Scientists suspect this benefit is due to more than just the effects of weight loss, but it’s still unknown how that occurs, why obesity raises the risk of developing cancer, or what cancer patients should eat to make their treatments more effective.
Project FEAST will connect researchers at both institutions who are advancing a new field of precision nutrition to answer those questions, studying how diet works at the molecular level to influence the development, progression, and treatment of pancreatic cancer, one of the deadliest forms of cancer.
The use of big data and machine learning is expected to transform cancer research and care in the next decade. The combined strengths of UCSF’s and Stanford’s data infrastructure and analysis capabilities will provide a new level of understanding of the diagnoses, outcomes, demographics, and cancer burden of the communities we serve.
Project IMPACT will use data sets from the University of California’s Bakar Computational Health Sciences Institute and the UC Cancer Consortium — along with Stanford’s Human-Centered Artificial Intelligence Initiative — to find ways to personalize cancer treatment.
“By uniting the innovative research efforts of UCSF and Stanford Medicine, the Weill Cancer Hub West stands to accelerate cancer care and treatment," said Steven Artandi, MD, PhD, the Laurie Kraus Lacob Director of the Stanford Cancer Institute. “By fostering a vibrant ecosystem of shared knowledge and resources and drawing from the lessons of past successes, we can propel toward a future where cancer is no longer a formidable foe."
*As of July 23
About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF's primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. UCSF School of Medicine also has a regional campus in Fresno. Learn more at ucsf.edu, or see our Fact Sheet.
About Stanford Medicine: Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.
###
Follow UCSF
ucsf.edu | Facebook.com/ucsf | YouTube.com/ucsf
END
Gift launches $200 million initiative for Weill Cancer Hub West
2025-07-23
ELSE PRESS RELEASES FROM THIS DATE:
This temporary tattoo could detect an unwanted drug in your drink
2025-07-23
Temporary tattoos aren’t just for kids anymore — semi-permanent versions have become a favorite among adults who don’t want the commitment of the real thing. Now, researchers reporting in ACS Sensors have created their own temporary tattoo sticker that has a hidden, but possibly lifesaving, purpose: detecting the presence of one drug used to “spike” alcoholic beverages and facilitate sexual assault. The sticker responds within 1 second to even low concentrations of the drug γ-hydroxybutyrate (GHB).
Unfortunately, consuming a drink spiked with drugs including Rohypnol (commonly known as ...
Screening for cardiovascular disease marker in community health centers may reduce risk
2025-07-23
DALLAS, July 23, 2025 — Elevated lipoprotein(a), also known as Lp(a), is an independent, inherited and causal risk factor for cardiovascular disease, the leading cause of death and disability worldwide.[1] Lp(a) is similar to low-density lipoprotein (LDL), or “bad” cholesterol, yet is caused by genetics and is not impacted by lifestyle modifications.
While it is estimated that 1 in 5 Americans have high Lp(a) levels, many people are not aware of their risk. Research has found less than 1% of people with atherosclerotic cardiovascular disease (ASCVD), which is caused by plaque buildup in the arteries, ...
Watermarks offer no defense against deepfakes
2025-07-23
New research from the University of Waterloo’s Cybersecurity and Privacy Institute demonstrates that any artificial intelligence (AI) image watermark can be removed, without the attacker needing to know the design of the watermark, or even whether an image is watermarked to begin with.
As AI-generated images and videos became more realistic, citizens and legislators are increasingly concerned about the potential impact of “deepfakes” across politics, the legal system and everyday life.
“People want a way ...
Pusan National University researchers investigate how air pollution triggers immune imbalance and lung damage
2025-07-23
Air pollution is a global health concern, with over 90% of the world’s population breathing air that exceeds World Health Organization safety standards. Fine and coarse particulate matter are especially dangerous, as they can penetrate deep into the lungs and bloodstream. While the link between air pollution and respiratory diseases is well established, how these pollutants disrupt immune responses in the lungs has remained unclear.
In a recent study, a team of researchers led by Professor Changwan Hong from Pusan National University ...
New study validates insulin nasal spray to deliver Alzheimer’s drug directly to the brain
2025-07-23
WINSTON-SALEM, N.C., July 23, 2025 — A groundbreaking brain imaging study from Wake Forest University School of Medicine confirms a vital step toward new Alzheimer’s disease treatments: Intranasal insulin, delivered via a simple nasal spray, safely and effectively reaches key memory regions of the brain in older adults. The study also revealed that people with early cognitive decline absorb it differently.
This research, published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, describes the ...
Hidden in plain sight: A century-old museum specimen turns out to be a landmark in evolution
2025-07-23
In a twist worthy of a detective novel, a long-misidentified fossil at Harvard’s Museum of Comparative Zoology (MCZ) has emerged as a key discovery in early animal evolution. Originally described in 1865 as a caterpillar, Palaeocampa anthrax shuffled between classifications—worm, millipede, and eventually a marine polychaete—until 130 years later, when researchers realized its true identity: the first-known nonmarine lobopodian and the earliest one ever discovered.
Lobopodians are extinct, soft-bodied creatures that bridge the evolutionary gap between a primitive worm-like ancestor and modern ...
People with substance use disorder were 24% more likely to require unplanned hospital readmission within 30 days of previous discharge
2025-07-23
People with any type of substance use disorder (SUD) stand a 24% higher risk of having an unplanned hospital readmission within 30 days of a previous discharge compared with those without the disorder, new UCLA-led research finds.
People with opioid use disorder had the highest 30-day readmission rates, at nearly 40%, the researchers found. Overall, people with SUDs comprise a disproportionate share of patients with multiple unplanned readmissions.
The higher risk was true only for people with substance use disorders who were discharged to homes without having been provided with post-acute care, said study co-author Steven Shoptaw, director of the Center for ...
New study brings vaccine hopes for deadly Nipah virus
2025-07-23
Scientists at The Pirbright Institute have taken a major step forward in tackling one of the world’s most dangerous viruses, the Nipah virus, by evaluating vaccine candidates for pigs.
The Nipah virus is zoonotic, meaning it can be transmitted from animals to humans. Originating in Old World fruit bats, the virus primarily affects pigs and humans.
The virus was first identified during a major outbreak in 1998-99 in Malaysia which led to the culling of nearly half the country's pig population and resulted in significant economic losses.
Since then, the virus has continued to cause outbreaks in South and Southeast ...
Can a compound produced by deep-sea bacteria treat cancer?
2025-07-23
Promoting pyroptosis—an inflammatory form of programmed cell death—has become a promising treatment strategy for cancer. In research published in The FASEB Journal, investigators purified a long-chain sugar molecule, or exopolysaccharide, from deep-sea bacteria and demonstrated that it triggers pyroptosis to inhibit tumor growth.
The compound, called EPS3.9, consists of mannose and glucose and is produced by the Spongiibacter nanhainus CSC3.9 bacterial strain and other members of the genus ...
How does infection with respiratory syncytial virus affect the health of older adults?
2025-07-23
Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it’s understudied in older individuals. In a retrospective study published in the Journal of the American Geriatrics Society, adults aged 65 and older hospitalized for RSV in Ontario, Canada experienced significantly higher rates of adverse outcomes such as longer length of hospital stay, transfer to intensive care, and 30-day mortality, compared with patients hospitalized with influenza, urinary tract infection, or fracture.
Interestingly, RSV hospitalization was also associated with higher rates of heart failure and atrial fibrillation up to 1-year post-discharge, regardless ...